6971:TSEKyocera Corporation Analysis
Data as of 2026-05-20 - not real-time
¥2,921.00
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
Technical momentum is strong: the stock is trading above both the 20‑day and 50‑day simple moving averages, the MACD line sits above its signal line, and the RSI is in the upper half of its range, all while volume is increasing, suggesting bullish short‑term pressure. Beta is low and volatility is moderate, indicating the price moves are less correlated with broader market swings.
Valuation and fundamentals signal caution: the market price is well above the DCF‑derived fair value, implying a notable overvaluation despite a PE that is marginally below the industry average. The dividend yield is modest but the payout ratio around half of earnings, combined with solid cash flows, points to sustainability. Overall, the stock sits near its 52‑week high with limited upside and moderate risk.
Valuation and fundamentals signal caution: the market price is well above the DCF‑derived fair value, implying a notable overvaluation despite a PE that is marginally below the industry average. The dividend yield is modest but the payout ratio around half of earnings, combined with solid cash flows, points to sustainability. Overall, the stock sits near its 52‑week high with limited upside and moderate risk.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Price already near 52‑week high with limited upside
- Bullish technical setup but overvaluation concerns
- Increasing volume supports current price level
Medium Term
1–3 yearsNeutral
Model confidence: 5/10
Key Factors
- Valuation gap between market price and DCF fair value
- Sustained dividend payout and solid cash flow
- Moderate volatility and low beta reduce market‑wide risk
Long Term
> 3 yearsPositive
Model confidence: 7/10
Key Factors
- Fundamental strengths in diversified product lines and global footprint
- Dividend sustainability provides income while waiting for price correction
- Potential for valuation re‑rating if price aligns closer to intrinsic value
Key Metrics & Analysis
Financial Health
Revenue Growth4.90%
Profit Margin6.81%
P/E Ratio28.4
ROE4.38%
ROA1.61%
Debt/Equity9.88
P/B Ratio1.2
Op. Cash Flow¥226.2B
Free Cash Flow¥27.1B
Industry P/E29.2
Technical Analysis
TrendBullish
RSI64.5
Support¥2,590.00
Resistance¥2,986.00
MA 20¥2,795.33
MA 50¥2,627.77
MA 200¥2,263.45
MACDBullish
VolumeIncreasing
Fear & Greed Index89.13
Valuation
Fair Value¥448.00
Target Price¥2,457.50
Upside/Downside-15.87%
GradeOvervalued
TypeBlend
Dividend Yield1.92%
Risk Assessment
Beta0.44
Volatility27.29%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.